{
  "ticker": "JNJ",
  "target_date": "2025-01-17",
  "actual_date": "2025-01-17",
  "collected_at": "2025-12-08T11:17:26.479830",
  "price": {
    "open": 143.06,
    "high": 143.97,
    "low": 142.26,
    "close": 142.66297912597656,
    "volume": 10773100,
    "change_1d_pct": -0.5,
    "change_7d_pct": 0.55,
    "change_30d_pct": -3.5
  },
  "technicals": {
    "rsi_14": 54.03,
    "sma_20": 140.4,
    "sma_50": 144.54,
    "macd": -0.88,
    "macd_signal": -1.565,
    "macd_histogram": 0.685,
    "bb_upper": 143.13,
    "bb_lower": 137.66,
    "price_vs_sma20_pct": 1.61,
    "price_vs_sma50_pct": -1.3,
    "volume_ratio": 1.3
  },
  "fundamentals": {
    "market_cap": 489002565632,
    "pe_ratio": 19.591217,
    "forward_pe": 19.14764,
    "price_to_book": 6.1603484,
    "price_to_sales": 5.306651,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.33,
    "pct_from_52w_low": 44.27
  },
  "macro": {
    "spy": {
      "price": 592.39,
      "change_1d_pct": 1.0,
      "change_7d_pct": 1.37
    },
    "vix": {
      "level": 15.97,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.61
    },
    "dollar_index": {
      "level": 109.35
    },
    "gold": {
      "price": 2744.3
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Mayar Capital Q2 2024 Letter To Partners",
      "source": "SeekingAlpha",
      "datetime": 1737107518,
      "summary": "Learn about Mayar Capital's investment management services and Responsible Global Equity Fund performance, along with lessons from historical market...",
      "url": "https://finnhub.io/api/news?id=17ff69ec35960d2bb2d92e1a4a75b40775719cd3e34ca2e940fa260c3917e038"
    },
    {
      "headline": "Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves",
      "source": "SeekingAlpha",
      "datetime": 1737026944,
      "summary": "Johnson & Johnson has underperformed its lerge-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Read my JNJ earnings preview.",
      "url": "https://finnhub.io/api/news?id=191aa74c86baf16d21f87696d693298aebe548ce810a2ade9f5bfb5184359083"
    },
    {
      "headline": "RYBREVANT\u00ae plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer",
      "source": "Finnhub",
      "datetime": 1737018726,
      "summary": "Phase 3 MARIPOSA-2 study showed RYBREVANT\u00ae in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone.1TORONTO, Jan....",
      "url": "https://finnhub.io/api/news?id=f40a26a74400d858abb9b5e6c19f1bfead53d7e18956e26bde6385a9eb5aa0ba"
    },
    {
      "headline": "The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems",
      "source": "SeekingAlpha",
      "datetime": 1737012600,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5e0c411f9de2843b78a5b97dcf88016ff7b1090acda1e12e74f0b9cdde168eb0"
    },
    {
      "headline": "Tempering Positive Sentiment Of AI In Biotech",
      "source": "SeekingAlpha",
      "datetime": 1737007436,
      "summary": "AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=cd2ce10465b2022ad38901994024c990f366b0e2333aac6670be174216a19808"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734042449.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000106/xslF345X05/wk-form4_1734042449.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041779.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000104/xslF345X05/wk-form4_1734041779.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041373.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000102/xslF345X05/wk-form4_1734041373.xml"
    },
    {
      "form": "13F-HR",
      "date": "2024-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445424000604/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "10-Q",
      "date": "2024-10-23",
      "description": "jnj-20240929.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000096/jnj-20240929.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}